<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04046029</url>
  </required_header>
  <id_info>
    <org_study_id>PJ-KS-KY-2019-38(X)</org_study_id>
    <nct_id>NCT04046029</nct_id>
  </id_info>
  <brief_title>Bivalirudin in Elderly Patients Undergoing Elective Percutaneous Coronary Intervention.</brief_title>
  <official_title>Bivalirudin vs Heparin in Elderly Patients With Acute Coronary Syndrome Undergoing Elective Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Affiliated Hospital of Dalian Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is an investigator-sponsored, prospective, multicenter, randomized, open-label
      study designed to compare efficacy and safety between bivalirudin and heparin in elderly
      patients with acute coronary syndrome undergoing elective percutaneous coronary intervention.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 8, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse cardiac events</measure>
    <time_frame>7 days</time_frame>
    <description>A composite of cardiac death, reinfarction, heart failure,ischemic stroke,frequent post infarction angina, Ventricular tachycardia or fibrillation requiring electrical cardioversion or defibrillation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>7 days</time_frame>
    <description>BARC types 3-5 bleeding;TIMI major bleeding or GUSTO moderate to severe bleeding.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac events</measure>
    <time_frame>30 days</time_frame>
    <description>A composite of cardiac death, reinfarction, heart failure,ischemic stroke,frequent post infarction angina, Ventricular tachycardia or fibrillation requiring electrical cardioversion or defibrillation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis ,TVR ,TLR</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of stent thrombosis,unplanned target-vessel revascularization and target lesion revascularisation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac events</measure>
    <time_frame>180 days</time_frame>
    <description>A composite of cardiac death, reinfarction, heart failure,ischemic stroke,frequent post infarction angina, Ventricular tachycardia or fibrillation requiring electrical cardioversion or defibrillation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis ,TVR ,TLR</measure>
    <time_frame>180 days</time_frame>
    <description>rate of stent thrombosis,unplanned target-vessel revascularization and target lesion revascularisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>30 days</time_frame>
    <description>BARC types 3-5 bleeding;TIMI major bleeding or GUSTO moderate to severe bleeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>180days</time_frame>
    <description>BARC types 3-5 bleeding;TIMI major bleeding or GUSTO moderate to severe bleeding.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <condition>Aging</condition>
  <condition>Anticoagulants and Bleeding Disorders</condition>
  <arm_group>
    <arm_group_label>Bivalirudin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bivalirudin</intervention_name>
    <description>Bivalirudin will be given as a bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg/h during the PCI procedure and for at least 30 minutes but no more than 4 hours afterwards. Following this mandatory infusion,a reduced-dose infusion (0.2 mg/kg/h) for up to 20 hours could be administered at physician discretion. An additional bivalirudin bolus of 0.3 mg/kg was given if the activated clotting time 5 minutes after the initial bolus was less than 225 seconds.</description>
    <arm_group_label>Bivalirudin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <description>Heparin will be administered at a dose of 70 to 100 units per kilogram in patients not receiving glycoprotein IIb/IIIa inhibitors and at a dose of 50 to 70 units per kilogram in patients receiving glycoprotein IIb/IIIa inhibitors. Subsequent adjustment of the heparin dose on the basis of the activated clotting time will be left to the discretion of the treating physicians.</description>
    <arm_group_label>Heparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥75 years old;

          -  Planned elective PCI for patients with acute coronary syndrome;

          -  Life expectancy ≥ 1 year;

          -  Provide written informed consent.

        Exclusion Criteria:

          -  Contraindications to angiography or PCI;

          -  Active bleeding or bleeding constitution, bleeding tendency, including GI or urinary
             tract hemorrhage (3 months), cerebral hemorrhage (6 months) or cerebral infarction
             history (3 months), etc;

          -  Other disease may lead to vascular lesions and secondary bleeding factors (such as
             active gastric ulcer, active ulcerative colitis, intra-cerebral mass, aneurysm, etc.);

          -  Severe renal insufficiency (eGFR &lt; 30 mL/min/ 1.73 m2);

          -  Elevated AST, ALT level higher than three times of the normal upper limit;

          -  Advanced heart failure (NYHA classification grading of cardiac function ≥Ⅲ)
             Complicated with immune system diseases#

          -  Abnormal hematopoietic system: platelet count &lt; 100 × 109 / L or &gt;700 × 109 / L, white
             blood cell count &lt; 3×109/L etc;

          -  Suffering from acute infections ,infectious diseases or other serious diseases, such
             as malignant tumors;

          -  Known intolerance, or contraindication to any antithrombotic medication

          -  Known allergy to the study drugs and instruments (UFH, bivalirudin, aspirin and
             clopidogrel, stainless steel, contrast agents, etc.), or those allergic constitution.

          -  Non-cardiac co-morbid conditions are present that may result in protocol
             non-compliance;

          -  Patients who are actively participating in another drug or device investigational
             study, which have not completed the primary endpoint follow-up period;

          -  Patient's inability to fully cooperate with the study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shaoke Meng, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Dalian Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shaoke Meng, M.D.</last_name>
    <phone>+86 18098875772</phone>
    <email>shaokemeng@dmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rongchong Huang, Ph.D.</last_name>
    <phone>+86 18841182000</phone>
    <email>rchuang@aliyun.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <zip>116011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Huang, M.D.</last_name>
      <phone>+86-411-83635963</phone>
      <phone_ext>3035</phone_ext>
      <email>dyyykjb@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Yinan Wang</last_name>
      <phone>+86-411-83635963</phone>
      <phone_ext>3015</phone_ext>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Verheugt FW, Weitz JI; European Society of Cardiology Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease. Parenteral anticoagulants in heart disease: current status and perspectives (Section II). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost. 2013 May;109(5):769-86. doi: 10.1160/TH12-06-0403. Epub 2013 Mar 28. Review.</citation>
    <PMID>23636477</PMID>
  </reference>
  <reference>
    <citation>Hirsh J, Anand SS, Halperin JL, Fuster V; American Heart Association. AHA Scientific Statement: Guide to anticoagulant therapy: heparin: a statement for healthcare professionals from the American Heart Association. Arterioscler Thromb Vasc Biol. 2001 Jul;21(7):E9-9.</citation>
    <PMID>11451763</PMID>
  </reference>
  <reference>
    <citation>Robson R, White H, Aylward P, Frampton C. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender. Clin Pharmacol Ther. 2002 Jun;71(6):433-9.</citation>
    <PMID>12087346</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>August 2, 2019</study_first_submitted>
  <study_first_submitted_qc>August 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2019</study_first_posted>
  <last_update_submitted>August 2, 2019</last_update_submitted>
  <last_update_submitted_qc>August 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Coronary Syndrome</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <keyword>Elderly</keyword>
  <keyword>Bivalirudin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Bivalirudin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

